BamSEC and AlphaSense Join Forces
Learn More

Introgen Therapeutics Inc

Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.65
from 10-Q 34 pages Introgen Therapeutics, Inc 6,000,000 Shares Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-10.64
from 10-Q 2 pages January 30, 2008 Mr. Bob Pearson 2001 Meandering River Court Austin, Texas 78746 Re: Business Development Arrangement Dear Bob
12/34/56
EX-10.18(D)
from 10-K 6 pages Employment Agreement
12/34/56
EX-10.63
from 10-Q 34 pages Introgen Therapeutics, Inc. Restricted Stock Purchase Agreement
12/34/56
EX-10.62
from 10-Q 41 pages Cooperative Research and Development Agreement (Crada 02177) Cooperative and Research Development Agreement for the Development of Introgen Proprietary Vectors and Recombinants for the Treatment of Cancer Steven A. Rosenberg, M.D., PH.D. Surgery Branch Center for Cancer Research National Cancer Institute Robert E. Sobol, M.D. Introgen Therapeutics, Inc. Prepared by Technology Transfer Branch National Cancer Institute Public Health Service Cooperative Research and Development Agreement for Intramural-Phs Clinical Research
12/34/56
EX-10.61
from 10-K 4 pages Amendment No. 5 to Patent and Technology License Agreement Dated July 31, 1994
12/34/56
EX-10.59
from 10-K 29 pages Patent and Technology License Agreement
12/34/56
EX-10.1
from 8-K 9 pages Introgen Therapeutics, Inc. Placement Agent Agreement
12/34/56
EX-10.1
from 8-K 9 pages Introgen Therapeutics, Inc. Placement Agent Agreement
12/34/56
EX-10.57
from 10-Q 4 pages Amendment No. 4 to Patent and Technology License Agreement Dated July 31, 1994
12/34/56
EX-10.56
from 8-K 4 pages Introgen Therapeutics Inc. 2000 Stock Option Plan Restricted Stock Purchase Agreement
12/34/56
EX-10.54
from 10-K 24 pages Common Stock Purchase Agreement
12/34/56
EX-10.53
from 10-K 25 pages Oral Healthcare Alliance Agreement
12/34/56
EX-10.55
from 8-K 2 pages Aventis Pharmaceuticals Inc. 300 Somerset Corporate Blvd. Bridgewater, New Jersey 08807 Re: Registration Rights Agreement Dated as of June 20, 2001, by and Among Introgen Therapeutics, Inc. (“Introgen”), Aventis Pharmaceuticals Inc. (“Aventis”) and Rhône-Poulenc Rorer International (Holdings), Inc. (The “Registration Rights Agreement”) Gentlemen
12/34/56
EX-10.52
from 10-Q 4 pages Suiter Limited P.O. Box 3176 Wickhams Cay 1 Road Town, Tortola British Virgin Islands Attn: Mr. Brunello Donati Re: Agreement (“Agreement”) Between Suiter Limited (“Suiter”) and Introgen Therapeutics, Inc. (The “Company”) Dated April 20, 2005 Dear Mr. Donati: This Will Confirm the Agreement of Suiter and the Company That Paragraph 2 of the Above-Referenced Agreement Is Hereby Amended and Restated to Read as Follows
12/34/56
EX-10.50
from 8-K 3 pages Introgen Therapeutics Inc. 2000 Stock Option Plan Stock Purchase Agreement
12/34/56
EX-10.50
from 10-Q 4 pages 20 April, 2005
12/34/56
EX-10.49
from 8-K 4 pages Dear Sirs Proposed Subscription for Shares in Sr Pharma PLC
12/34/56
EX-10.48
from 8-K 3 pages Introgen Therapeutics Inc. 2000 Stock Option Plan Stock Purchase Agreement
12/34/56
EX-10.47
from 8-K 3 pages Introgen Therapeutics Inc. 2000 Stock Option Plan Stock Purchase Agreement
12/34/56